SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss)

The table below includes information about the Company’s segment, including significant segment expenses and a reconciliation to net (loss) income:


	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
							(in thousands)
Total revenues	$	401,251		$	611,091		$	1,132,054		$	1,355,947

Segment expenses and other segment items:
Cost of sales (excluding amortization of in-licensed rights)		149,385			152,558			258,153			290,122
Compensation and other personnel expenses		60,725			89,839			122,655			182,923
Up-front and collaboration license fees		—			—			50,000			583,787
Manufacturing expenses		1,837			80,685			21,595			148,150
Clinical trial expenses		23,102			33,511			41,406			66,658
Facility- and technology-related expenses (excluding depreciation and amortization)		23,890			28,580			46,832			56,237
Research and development- other (excluding non-cash items) (1)		19,847			31,843			38,518			60,314
Selling, general and administrative- other (excluding non-cash items) (2)		42,462			56,322			82,655			107,464
Roche collaboration reimbursement		(7,169	)		(25,689	)		(15,358	)		(54,170	)
Other segment items (3)		(709	)		(1,314	)		(2,515	)		(3,223	)
Loss (gain) on strategic investments		448			(36,721	)		2,160			54,007
Interest expense		21,508			5,228			43,221			9,731
Interest income		(6,207	)		(5,254	)		(12,567	)		(15,444	)
Income tax expense (benefit)		3,141			(43,254	)		15,356			20,736
Depreciation and amortization expense		10,409			10,840			21,003			20,818
Stock-based compensation expense		24,472			37,025			53,871			78,453
Litigation contingency charge		39,000			—			39,000			—
Segment net (loss) income	$	(4,890	)	$	196,892		$	326,069		$	(250,616	)

Reconciliation of profit or loss
Adjustments and reconciling items		—			—			—			—
Consolidated net (loss) income	$	(4,890	)	$	196,892		$	326,069		$	(250,616	)

(1)

Research and development-other includes professional services, pre-clinical expenses and research and other expenses.

(2)

Selling, general and administrative-other includes professional services and other expenses.

(3)

Other segment items included in segment net (loss) income include accretion of investment discount, net and other, net, as well as items separately presented and not defined as significant expenses below.

Significant expense categories that are regularly provided to the CODM include cost of sales (excluding amortization of in-licensed rights), compensation and other personnel expenses, up-front and collaboration license expenses, manufacturing expenses, clinical trial expenses, facility- and technology-related expenses, research and development- other and selling, general and administrative- other. The other expense or income information are other segment items and include separate presentation of loss (gain) on strategic investments, interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense and litigation contingency charge, which are included in the measure of segment net (loss) income, but are not significant segment expenses.

Assets provided to the CODM for the single segment are consistent with those reported on the unaudited condensed consolidated balance sheets.